Outpatient Department

Medical research at the Outpatient Department contributes to the understanding of disease-relevant mechanisms in order to improve prevention and therapy.

Profile picture

Head of Department Systems Toxicology

Much of the research at IfADo is conducted on cell cultures and animal models. The question often arises as to how relevant the mechanisms discovered in this way are for humans. To better answer this question, the Outpatient Department has established a clinical network and has extensive access to human tissue banks. Examples of our activities:

  • Blood samples, e.g. from patients after overdose of hepatotoxic drugs have led to the discovery of new mechanisms of hepatotoxicity (Ghallab et al., 2022).
  • A particular focus is liver tissue with disease-relevant information, which we are investigating together with the Bioanalytics Department (Schneider et al., 2021; Mohs et al., 2021; Remetic et al., 2022; Ramisch et al., 2019).
  • Isolated single cells from human organs, e.g. liver cells (Nell et al., 2022).
  • Tissue from human tumours (Almstedt et al., 2022).

Furthermore, the Outpatient Department has experience in organising clinical trials (Edlund et al., 2021) and has facilities for medical interventions and diagnostics.


Almstedt K, Heimes AS, Kappenberg F, Battista MJ, Lehr HA, Krajnak S, Lebrecht A, Gehrmann M, Stewen K, Brenner W, Weikel W, Rahnenführer J, Hengstler JG, Hasenburg A, Schmidt M: Long-term prognostic significance of HER2-low and HER2-zero in node-negative breast cancer. Eur J Cancer 173: 10-19 (2022).Doi:

Edlund K, Madjar K, Lebrecht A, Aktas B, Pilch H, Hoffmann G, Hofmann M, Kolberg HC, Boehm D, Battista MJ, Seehase M, Stewen K, Gebhard S, Cadenas C, Marchan R, Brenner W, Hasenburg A, Koelbl H, Solbach C, Gehrmann M, Tanner B, Weber K, Loibl S, Sachinidis A, Rahnenführer J, Schmidt M, Hengstler JG: Gene expression-based prediction of neoadjuvant chemotherapy response in early breast cancer: results of the prospective multicenter EXPRESSION trial. Clin Cancer Res 27: 2148-2158 (2021). Doi:

Ghallab A, Hassan R, Hofmann U, Friebel A, Hobloss Z, Brackhagen L, Begher-Tibbe B, Myllys M, Reinders J, Overbeck N, Sezgin S, Zühlke S, Seddek AL, Murad W, Brecklinghaus T, Kappenberg F, Rahnenführer J, González D, Goldring C, Copple IM, Marchan R, Longerich T, Vucur M, Luedde T, Urban S, Canbay A, Schreiter T, Trauner M, Akakpo JY, Olyaee M, Curry SC, Sowa JP, Jaeschke H, Hoehme S, Hengstler JG: Interruption of bile acid uptake by hepatocytes after acetaminophen overdose ameliorates hepatotoxicity. J Hepatol 77: 71-83 (2022). Doi:

Mohs A, Otto T, Schneider KM, Peltzer M, Boekschoten M, Holland CH, Hudert CA, Kalveram L, Wiegand S, Saez-Rodriguez J, Longerich T, Hengstler JG, Trautwein C: Hepatocyte-specific NRF2 activation controls fibrogenesis and carcinogenesis in steatohepatitis. J Hepatol 74: 638-648 (2021). Doi:

Nell P, Kattler K, Feuerborn D, Hellwig B, Rieck A, Salhab A, Lepikhov K, Gasparoni G, Thomitzek A, Belgasmi K, Blüthgen N, Morkel M, Küppers-Munther B, Godoy P, Hay DC, Cadenas C, Marchan R, Vartak N, Edlund K, Rahnenführer J, Walter J, Hengstler JG: Identification of an FXR-modulated liver-intestine hybrid state in iPSC-derived hepatocyte-like cells. J Hepatol 77: 1386-1398 (2022). Doi:

Ramisch A, Heinrich V, Glaser LV, Fuchs A, Yang X, Benner P, Schöpflin R, Li N, Kinkley S, Römer-Hillmann A, Longinotto J, Heyne S, Czepukojc B, Kessler SM, Kiemer AK, Cadenas C, Arrigoni L, Gasparoni N, Manke T, Pap T, Pospisilik JA, Hengstler J, Walter J, Meijsing SH, Chung HR, Vingron M: CRUP: a comprehensive framework to predict condition-specific regulatory units. Genome Biol 20(1): 227 (2019) (23 pp). Doi:

Remetic J, Ghallab A, Hobloss Z, Brackhagen L, Hassan R, Myllys M, Radun R, Mlitz V, Zhu C, Baumgartner M, Schrottmaier WC, Mussbacher M, Timelthaler G, Scharnagl H, Stojakovic T, Assinger A, Fuchs CD, Hengstler JG, Trauner M: Loss of bile salt export pump aggravates lipopolysaccharide-induced liver injury in mice due to impaired hepatic endotoxin clearance. Hepatology 75: 1095-1109 (2022). Doi:

Schneider KM, Candels LS, Hov JR, Myllys M, Hassan R, Schneider CV, Wahlström A, Mohs A, Zühlke S, Liao L, Elfers C, Kilic K, Henricsson M, Molinaro A, Hatting M, Zaza A, Drasdo D, Frissen M, Devlin AS, Gálvez EJC, Strowig T, Karlsen TH, Hengstler JG, Marschall HU, Ghallab A, Trautwein C: Gut microbiota depletion exacerbates cholestatic liver injury via loss of FXR signalling. Nat Metab 3 (9):1228-1241 (2021). Doi: